With Novartis and Roche gunning to carve up Eylea franchise, Regeneron has another PhIII success story to tell
Working furiously to stay ahead of two powerhouse rivals in Novartis and Roche, Regeneron today is running out a promising set of fresh top-line data for its franchise drug Eylea. And one prominent analyst quickly rewarded them with a projection of $700 million in added sales in 5 years.
Researchers led by chief scientific officer George Yancopoulos say they hit the primary endpoint in their Phase III study for severe non-proliferative diabetic retinopathy, setting up a supplemental application at the FDA.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
